Statement of Changes in Beneficial Ownership (4)
April 19 2023 - 5:36PM
Edgar (US Regulatory)
FORM 4
☐
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Shaker Benjamin |
2. Issuer Name and Ticker or Trading Symbol
agilon health, inc.
[
AGL
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Markets Officer |
(Last)
(First)
(Middle)
C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/17/2023 |
(Street)
AUSTIN, TX 78723 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
(City)
(State)
(Zip)
|
Rule 10b5-1(c) Transaction Indication
☒
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to
satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 4/17/2023 | | M | | 1851 | A | $1.00 | 81394 (1) | D | |
Common Stock | 4/17/2023 | | M | | 23149 | A | $3.00 | 104543 (1) | D | |
Common Stock | 4/17/2023 | | S(2) | | 23600 | D | $27.6966 (3) | 80943 (1) | D | |
Common Stock | 4/17/2023 | | S(2) | | 1400 | D | $28.5407 (4) | 79543 (1) | D | |
Common Stock | 4/18/2023 | | M | | 25000 | A | $3.00 | 104543 (1) | D | |
Common Stock | 4/18/2023 | | S(2) | | 25000 | D | $28.0452 (5) | 79543 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Options (Right to buy) | $1.00 | 4/17/2023 | | M | | | 1851 | (6) | 4/27/2027 | Common Stock | 1851 | $0.00 | 0 | D | |
Options (Right to buy) | $3.00 | 4/17/2023 | | M | | | 23149 | (7) | 4/27/2027 | Common Stock | 23149 | $0.00 | 76851 | D | |
Options (Right to buy) | $3.00 | 4/18/2023 | | M | | | 25000 | (7) | 4/27/2027 | Common Stock | 25000 | $0.00 | 51851 | D | |
Explanation of Responses: |
(1) | Includes restricted stock units. |
(2) | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan effective 15 Sept. 2022. |
(3) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.42 to $28.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
(4) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.46 to $28.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
(5) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.64 to $28.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
(6) | These options were granted on April 27, 2017, and became fully vested as of January 12, 2021. |
(7) | These options were granted on April 27, 2017, and became fully vested as of September 14, 2021. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Shaker Benjamin C/O AGILON HEALTH, INC. 6210 E HWY 290, SUITE 450 AUSTIN, TX 78723 |
|
| Chief Markets Officer |
|
Signatures
|
/s/ Steve Meetre, as Attorney-in-Fact | | 4/19/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Agilon Health (NYSE:AGL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Agilon Health (NYSE:AGL)
Historical Stock Chart
From Nov 2023 to Nov 2024